ArticleNeuro-oncology2018
Insurance correlates with improved access to care and outcome among glioblastoma patients.
Article in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Neighborhood material deprivation and days at home after glioblastoma diagnosis.Journal of neuro-oncology · 2026Article
- An analysis of the influence of social determinants of health on treatment and survival among adult patients with high-grade glioma in Utah.Neuro-oncology practice · 2025Article
- Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005-2020).Brain sciences · 2025Article
- Economic income and survival in patients affected by glioblastoma: A systematic review and meta-analysis.Neuro-oncology practice · 2024Review
- Challenges and Opportunities in Accessing Surgery for Glioblastoma in Low-Middle Income Countries: A Narrative Review.Cancers · 2024Article
- Social determinants of health and incident postoperative delirium: Exploring key relationships in the SAGES study.Journal of the American Geriatrics Society · 2024Article
- Glioblastoma management in a lower middle-income country: Nationwide study of compliance with standard care protocols and survival outcomes in Ukraine.Neuro-oncology practice · 2023Article
- Area-level socioeconomic status is positively correlated with glioblastoma incidence and prognosis in the United States.Frontiers in oncology · 2023Review
- Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI).Journal of neuro-oncology · 2022Article
- Distinct survival and clinical profile of infantile glioblastoma: insights from a national database.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Article
- Socioeconomic and demographic determinants of radiation treatment and outcomes in glioblastoma patients.Frontiers in neurology · 2022Article
- Social determinants of health and survival on Brazilian patients with glioblastoma: a retrospective analysis of a large populational database.Lancet regional health. Americas · 2021Article
- Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US.Journal of neuro-oncology · 2021Article
- Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database.Frontiers in oncology · 2021Article
- Geographic and socioeconomic considerations for glioblastoma treatment in the elderly at a national level: a US perspective.Neuro-oncology practice · 2020Article
- Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry.Journal of neuro-oncology · 2020Article
- Community economic factors influence outcomes for patients with primary malignant glioma.Neuro-oncology practice · 2020Article
- Article
- Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013.Journal of neuro-oncology · 2020Article
- Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.World neurosurgery · 2020Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The current standard of care for glioblastoma (GBM) constitutes maximal safe surgical resection, followed by fractionated radiation and temozolomide. This treatment regimen is logistically burdensome, and in a health care system in which access to care is variable, there may be patients with worsened outcomes due to inadequate access to optimal treatment. Methods: The National Cancer Database was queried for patients with diagnoses of GBM in 2006-2014. Patients were grouped according to insurance status: private insurance, Medicare, Medicaid, or uninsured. Treatments provided (surgery, radiation, and chemotherapy) were compared between groups in univariate and multivariable logistic regression analysis. Results: A total of 61614 patients were analyzed. Compared with private insurance, the odds of surgery for Medicaid and uninsured patients were 0.72 (95% CI: 0.66-0.79) and 0.77 (95% CI: 0.69-0.87), respectively (P < 0.001). The multivariable odds of receiving radiotherapy were 0.91 (95% CI: 0.86-0.96), 0.62 (95% CI: 0.57-0.68), and 0.47 (95% CI: 0.43-0.52) for Medicare, Medicaid, and uninsured patients, respectively (all P < 0.001). In addition, the odds of receiving chemotherapy were 0.94 (95% CI: 0.89-0.99), 0.53 (95% CI: 0.49-0.57), and 0.41 (95% CI: 0.38-0.46) for Medicare, Medicaid, and uninsured patients, respectively (all P < 0.001). Conclusion: Insurance status and type of insurance coverage appear to impact treatments rendered for GBM, independently of other variables. Furthermore, we find that such differential access to care significantly impacts survival. Ensuring adequate access to care for all patients with diagnoses of glioblastoma is critical to optimize survival, especially as therapies continue to advance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.